Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Milestone Pharmaceuticals Inc
MIST | US
2.09
USD-0.11
-5.00%
MIST | US
Loading StockChartView...
About Milestone Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
2.09
Open
2.21
High
2.34
Low
2.08
Milestone Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil a novel and potent calcium channel blocker which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal Canada.
View LessMIST | US
Risk
143.3
Sharpe
1.67
Luna's Score
42/100
Recommendation
Sell
Luna says (MIST | US)
What's Working
Positive Momentum
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
91.8%1 month
143.3%3 months
92.3%6 months
83.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.48
Debt to equity
1.67
Debt to assets
0.60
Ent. to EBITDA
-1.43
Ent. to rev.
81.44
PEG
-
Other Fundamentals
EBITDA
-49.19M
MarketCap
111.33M
MarketCap(USD)
111.33M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-133.75
Short ratio
3.33
Short perc.
0.83
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.09
Range1M
1.34
Range3M
1.34
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.02
Price X volume
6.76M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.43 | 0.53 | Cheaper |
| Ent. to Revenue | 81.44 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.48 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 92.33 | 72.80 | Riskier |
| Debt to Equity | 1.67 | -1.23 | Expensive |
| Debt to Assets | 0.60 | 0.25 | Expensive |
| Market Cap | 111.33M | 3.66B | Emerging |
